Molecular and Cellular Biochemistry

, Volume 400, Issue 1–2, pp 125–133 | Cite as

Sphingosine 1-phosphate lyase inhibition by 2-acetyl-4-(tetrahydroxybutyl)imidazole (THI) under conditions of vitamin B6 deficiency

  • Mamoru Ohtoyo
  • Masakazu Tamura
  • Nobuo Machinaga
  • Fumihito Muro
  • Ryuji Hashimoto
Article

Abstract

Caramel food colorant 2-acetyl-4-(tetrahydroxybutyl)imidazole (THI) causes lymphopenia in animals through sphingosine 1-phosphate lyase (SPL) inhibition. However, this mechanism of action is partly still controversial because THI did not inhibit SPL in vitro either in cell-free or in cell-based systems. It is thought that the in vitro experimental conditions which have been used so far were not suitable for the evaluation of SPL inhibition, especially in case of cell-based experiments. We speculated that the key factor might be the coenzyme pyridoxal 5′-phosphate (PLP), an active form of vitamin B6 (VB6), because media used in cell-based assays usually contain an excess amount of VB6 which leads to the activation of SPL. By the use of VB6-deficient culture medium, we could regulate apo- (without PLP) and holo- (with PLP) SPL enzyme in cultured cells, resulting in the successful detection of SPL inhibition by THI. Although the observed inhibitory effect was not as strong as that of 4-deoxypyridoxine (a VB6 analog SPL inhibitor), these findings may be useful for further understanding the mechanism of action of THI.

Keywords

2-Acetyl-4-(tetrahydroxybutyl)imidazole Sphingosine 1-phosphate S1P lyase Vitamin B6 4-Deoxypyridoxine 

Supplementary material

11010_2014_2268_MOESM1_ESM.xlsx (80 kb)
Supplementary material 1 (XLSX 79 kb)

References

  1. 1.
    Sinkeldam EJ, de Groot AP, van den Berg H, Chappel CI (1988) The effect of pyridoxine on the number of lymphocytes in the blood of rats fed caramel colour (III). Food Chem Toxicol 26:195–203CrossRefPubMedGoogle Scholar
  2. 2.
    Gobin SJ, Paine AJ (1989) Effect of oral and parenteral administration of B6 vitamers on the lymphopenia produced by feeding ammonia caramel or 2-acetyl-4(5)-(1,2,3,4-tetrahydroxy)butylimidazole to rats. Food Chem Toxicol 27:627–630CrossRefPubMedGoogle Scholar
  3. 3.
    Iscaro A, Mackay IR, O’Brien C (1988) Lymphopenic effects on mice of a component of ammonia caramel, 2-acetyl-4(5)-tetrahydroxybutylimidazole (THI). Immunol Cell Biol 66:395–402CrossRefPubMedGoogle Scholar
  4. 4.
    Gobin SJ, Phillips JA (1991) Immunosuppressive effects of 2-acetyl-4-tetrahydroxybutyl imidazole (THI) in the rat. Clin Exp Immunol 85:335–340PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Gugasyan R, Coward A, O’Connor L, Shortman K, Scollay R (1998) Emigration of mature T cells from the thymus is inhibited by the imidazole-based compound 2-acetyl-4-tetrahydroxybutylimidazole. Immunology 93:398–404PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Schwab SR, Pereira JP, Matloubian M, Xu Y, Huang Y, Cyster JG (2005) Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 309:1735–1739CrossRefPubMedGoogle Scholar
  7. 7.
    Schwab SR, Cyster JG (2007) Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol 8:1295–1301CrossRefPubMedGoogle Scholar
  8. 8.
    Bagdanoff JT, Donoviel MS, Nouraldeen A et al (2010) Inhibition of sphingosine 1-phosphate lyase for the treatment of rheumatoid arthritis: discovery of (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime (LX2931) and (1R,2S,3R)-1-(2-(isoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol (LX2932). J Med Chem 53:8650–8662CrossRefPubMedGoogle Scholar
  9. 9.
    Bagdanoff JT, Donoviel MS, Nouraldeen A et al (2009) Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders. J Med Chem 52:3941–3953CrossRefPubMedGoogle Scholar
  10. 10.
    Reina E, Camacho L, Casas J, Van Veldhoven PP, Fabrias G (2012) Determination of sphingosine-1-phosphate lyase activity by gas chromatography coupled to electron impact mass spectrometry. Chem Phys Lipids 165:225–231CrossRefPubMedGoogle Scholar
  11. 11.
    Bassi R, Anelli V, Giussani P, Tettamanti G, Viani P, Riboni L (2006) Sphingosine-1-phosphate is released by cerebellar astrocytes in response to bFGF and induces astrocyte proliferation through Gi-protein-coupled receptors. Glia 53:621–630CrossRefPubMedGoogle Scholar
  12. 12.
    Sensken SC, Bode C, Nagarajan M, Peest U, Pabst O, Gräler MH (2010) Redistribution of sphingosine 1-phosphate by sphingosine kinase 2 contributes to lymphopenia. J Immunol 184:4133–4142CrossRefPubMedGoogle Scholar
  13. 13.
    Berdyshev EV, Gorshkova I, Usatyuk P, Kalari S, Zhao Y, Pyne NJ, Pyne S, Sabbadini RA, Garcia JG, Natarajan V (2011) Intracellular S1P generation is essential for S1P-induced motility of human lung endothelial cells: role of sphingosine kinase 1 and S1P lyase. PLoS ONE 6:e16571PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Billich A, Beerli C, Bergmann R, Bruns C, Loetscher E (2013) Cellular assay for the characterization of sphingosine-1-phosphate lyase inhibitors. Anal Biochem 434:247–253CrossRefPubMedGoogle Scholar
  15. 15.
    Loetscher E, Schneider K, Beerli C, Billich A (2013) Assay to measure the secretion of sphingosine-1-phosphate from cells induced by S1P lyase inhibitors. Biochem Biophys Res Commun 433:345–348CrossRefPubMedGoogle Scholar
  16. 16.
    Mukhopadhyay D, Howell KS, Riezman H, Capitani G (2008) Identifying key residues of sphinganine-1-phosphate lyase for function in vivo and in vitro. J Biol Chem 283:20159–20169CrossRefPubMedGoogle Scholar
  17. 17.
    Nussbaumer P (2008) Medicinal chemistry aspects of drug targets in sphingolipid metabolism. ChemMedChem 3:543–551CrossRefPubMedGoogle Scholar
  18. 18.
    Serra M, Saba JD (2010) Sphingosine 1-phosphate lyase, a key regulator of sphingosine 1-phosphate signaling and function. Adv Enzyme Regul 50:349–362PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    van de Kamp JL, Westrick JA, Smolen A (1995) B-6 vitamer concentrations in mouse plasma, erythrocytes and tissues. Nutr Res 15:415–422CrossRefGoogle Scholar
  20. 20.
    Wei IL (1999) The influence of dietary restriction on vitamin B-6 vitamer distribution and on vitamin B-6 metabolizing enzymes in rats. J Am Coll Nutr 18:144–151CrossRefPubMedGoogle Scholar
  21. 21.
    Leklem JE (1990) Vitamin B-6: a status report. J Nutr 120:1503–1507PubMedGoogle Scholar
  22. 22.
    Itoh T, Doi H, Chin S, Nishimura T, Kasahara S (1988) Establishment of mouse thymic nurse cell clones from a spontaneous BALB/c thymic tumor. Eur J Immunol 18:821–824CrossRefPubMedGoogle Scholar
  23. 23.
    Long RF, Morrison AL (1954) The synthesis of 4-deoxypyridoxine phosphates. J Chem Soc 3854–3856. doi:10.1039/JR9540003854
  24. 24.
    Cliff MD, Pyne SG (1997) Asymmetric synthesis of 2-acetyl-4(5)-(1,2,3,4-tetrahydroxybutyl)imidazoles. J Org Chem 62:1023–1032CrossRefGoogle Scholar
  25. 25.
    Berdyshev EV, Gorshkova IA, Garcia JG, Natarajan V, Hubbard WC (2005) Quantitative analysis of sphingoid base-1-phosphates as bisacetylated derivatives by liquid chromatography–tandem mass spectrometry. Anal Biochem 339:129–136CrossRefPubMedGoogle Scholar
  26. 26.
    Ikeda M, Kihara A, Kariya Y, Lee YM, Igarashi Y (2005) Sphingolipid-to-glycerophospholipid conversion in SPL-null cells implies the existence of an alternative isozyme. Biochem Biophys Res Commun 329:474–479CrossRefPubMedGoogle Scholar
  27. 27.
    Hanna MC, Turner AJ, Kirkness EF (1997) Human pyridoxal kinase. cDNA cloning, expression, and modulation by ligands of the benzodiazepine receptor. J Biol Chem 272:10756–10760CrossRefPubMedGoogle Scholar
  28. 28.
    Soga T, Heiger DN (2000) Amino acid analysis by capillary electrophoresis electrospray ionization mass spectrometry. Anal Chem 72:1236–1241CrossRefPubMedGoogle Scholar
  29. 29.
    Soga T, Ueno Y, Naraoka H, Ohashi Y, Tomita M, Nishioka T (2002) Simultaneous determination of anionic intermediates for Bacillus subtilis metabolic pathways by capillary electrophoresis electrospray ionization mass spectrometry. Anal Chem 74:2233–2239CrossRefPubMedGoogle Scholar
  30. 30.
    Soga T, Ohashi Y, Ueno Y, Naraoka H, Tomita M, Nishioka T (2003) Quantitative metabolome analysis using capillary electrophoresis mass spectrometry. J Proteome Res 2:488–494CrossRefPubMedGoogle Scholar
  31. 31.
    Sugimoto M, Wong DT, Hirayama A, Soga T, Tomita M (2009) Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics 6:78–95PubMedCentralCrossRefPubMedGoogle Scholar
  32. 32.
    Meister A, Sober HA, Peterson EA (1954) Studies on the coenzyme activation of glutamic-aspartic apotransaminase. J Biol Chem 206:89–100PubMedGoogle Scholar
  33. 33.
    Trakatellis A, Dimitriadou A, Trakatelli M (1997) Pyridoxine deficiency: new approaches in immunosuppression and chemotherapy. Postgrad Med J 73:617–622PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    Said HM, Ortiz A, Ma TY (2003) A carrier-mediated mechanism for pyridoxine uptake by human intestinal epithelial Caco-2 cells: regulation by a PKA-mediated pathway. Am J Physiol Cell Physiol 285:C1219–C1225CrossRefPubMedGoogle Scholar
  35. 35.
    Shane B, Snell EE (1976) Transport and metabolism of vitamin B6 in the yeast Saccharomyces carlsbergensis 4228. J Biol Chem 251:1042–1051PubMedGoogle Scholar
  36. 36.
    Yu XQ, Kramer J, Moran L, O’Neill E, Nouraldeen A, Oravecz T, Wilson AG (2010) Pharmacokinetic/pharmacodynamic modelling of 2-acetyl-4(5)-tetrahydroxybutyl imidazole-induced peripheral lymphocyte sequestration through increasing lymphoid sphingosine 1-phosphate. Xenobiotica 40:350–356CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Mamoru Ohtoyo
    • 1
  • Masakazu Tamura
    • 2
  • Nobuo Machinaga
    • 3
  • Fumihito Muro
    • 4
  • Ryuji Hashimoto
    • 1
  1. 1.New Modality Research Laboratories, R&D DivisionDaiichi Sankyo Co., Ltd.TokyoJapan
  2. 2.Biologics Pharmacology Research Laboratories, R&D DivisionDaiichi Sankyo Co., Ltd.TokyoJapan
  3. 3.Medicinal Chemistry Research Laboratories, R&D DivisionDaiichi Sankyo Co., Ltd.TokyoJapan
  4. 4.Vaccine Business Strategy Department, Vaccine Business Intelligence DivisionDaiichi Sankyo Co., Ltd.TokyoJapan

Personalised recommendations